Neuroprotective Properties of Chlorogenic Acid and 4,5-Caffeoylquinic Acid from Brazilian arnica (Lychnophora ericoides) after Acute Retinal Ischemia

Abstract

Lychnophora is a genus of South American flowering plants in the daisy family, popularly known as “Brazilian arnica”. It is used in traditional medicine as an anti-inflammatory and analgesic agent, whose active components are derived from chlorogenic acid (CGA) and C-flavonoids. Since the drugs currently used are ineffective to treat glaucoma, agents with antioxidant and anti-inflammatory properties may represent new alternatives in preventing cellular lesions in retinal ischemia. In this study, we report the neuroprotective effects of CGA and 4,5-di-O-[E]-caffeoylquinic (CQA) acid, isolated from Lychnophora plants, in a rodent glaucoma model. Wistar rats were administered intravitreally with 10 µg CGA or CGA, and then subjected to acute retinal ischemia (ISC) by increasing intraocular pressure (IPO) for 45 minutes followed (or not) by 15 minutes of reperfusion (I/R). Qualitative and quantitative analyses of neurodegeneration were performed using hematoxylin-eosin or Fluoro-Jade C staining protocols. All retinas submitted to ISC or I/R exhibited matrix disorganization, pyknotic nuclei, and pronounced vacuolization of the cytoplasm in the ganglion cell layer (GCL) and inner nuclear layer (INL). Pretreatment with CGA or CQA resulted in the protection of the retinal layers against matrix disorganization and a reduction in the number of vacuolized cells and pyknotic nuclei. Also, pretreatment with CGA or CQA resulted in a significant reduction in neuronal death in the GCL, the INL, and the outer nuclear layer (ONL) after ischemic insult. Our study demonstrated that CGA and CQA exhibit neuroprotective activities in retinas subjected to ISC and I/R induced by IPO in Wistar rats.

Key words

Lychnophora ericoides, compositae - Asteraceae - 4,5-di-O-[E]-caffeoylquinic acid - chlorogenic acid - acute rat retinal ischemia - neuroprotection

Publikationsverlauf

Eingereicht: 28. März 2022

Angenommen nach Revision: 27. Juni 2022

Artikel online veröffentlicht:
11. Oktober 2022

• References

• 1 Keles LC, de Melo NI, Aguiar PG, Wakabayashi KAL, de Carvalho CE, Cunha WR, Crotti EAM, Luis J, Callegari Lopes JL, Lopes NP. Lychnophorinae (Asteraceae): A survey of its chemical constituents and biological activities. Quim Nova 2010; 33: 2245-2260 DOI: 10.1590/S0100-40422010001000038.
• 2 Gobbo-Neto L, Santos MD, Kanashiro A, Almeida MC, Lucisano-Valim YM, Lopes JL, Souza GE, Lopes NP. Evaluation of the anti-inflammatory and antioxidant activities of di-C-glucoflavones from Lychnophora ericoides (Asteraceae). Planta Med 2005; 71: 3-6 DOI: 10.1055/s-2005-837742.
• 3 dos Santos MD, Gobbo-Neto L, Albarella L, de Souza GE, Lopes NP. Analgesic activity of di-caffeoylquinic acids from roots of Lychnophora ericoides (Arnica da serra). J Ethnopharmacol 2005; 96: 545-549 DOI: 10.1016/j.jep.2004.09.043.
• 4 Taleb-Contini SH, Santos WF, Mortari MR, Lopes NP, Lopes JL. Neuropharmacological effects in mice of Lychnophora species (Vernonieae, Asteraceae) and anticonvulsant activity of 4, 5-di-O-[E]-caffeoylquinic acid isolated from the stem of L. rupestris and L. staavioides. Basic Clin Pharmacol Toxicol 2008; 102: 281-286 DOI: 10.1111/j.1742-7843.2007.00194.x.
• 5 Paiva MRB, Vasconcelos-Santos DV, Coelho MM, Machado RR, Lopes NP, Silva-Cunha A, Fialho SL. Licarin A as a novel drug for inflammatory eye diseases. J Ocul Pharmacol Ther 2021; 37: 290-300 DOI: 10.1089/jop.2020.0129.
• 6 Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology 2014; 121: 2081-2090 DOI: 10.1016/j.ophtha.2014.05.013.
• 7 Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: Drug-based approaches. Optom Vis Sci 2008; 85: 406-416 DOI: 10.1097/OPX.0b013e31817841e5.
• 8 Ermine CM, Bivard A, Parsons MW, Baron JC. The ischemic penumbra: From concept to reality. Int J Stroke 2021; 16: 497-509 DOI: 10.1177/1747493020975229.
• 9 Ige M, Liu J. Herbal Medicines in Glaucoma Treatment. Yale J Biol Med 2020; 93: 347-353
• 10 Pinazo-Duran MD, Shoaie-Nia K, Zanon-Moreno V, Sanz-Gonzalez SM, Del Castillo JB, Garcia-Medina JJ. Strategies to reduce oxidative stress in glaucoma patients. Curr Neuropharmacol 2018; 16: 903-918 DOI: 10.2174/1570159X15666170705101910.
• 11 Kobayashi H. Efficacy of single glaucoma drug in combined timolol XE, latanoprost and brinzolamide therapy: a discontinuation study. J Ocul Pharmacol Ther 2012; 28: 245-250 DOI: 10.1089/jop.2011.0128.
• 12 Jang H, Ahn HR, Jo H, Kim KA, Lee EH, Lee KW, Jung SH, Lee CY. Chlorogenic acid and coffee prevent hypoxia-induced retinal degeneration. J Agric Food Chem 2014; 62: 182-191 DOI: 10.1021/jf404285v.
• 13 dos Santos MD, Chen G, Almeida MC, Soares DM, de Souza GE, Lopes NP, Lantz RC. Effects of caffeoylquinic acid derivatives and C-flavonoid from Lychnophora ericoides on in vitro inflammatory mediator production. Nat Prod Commun 2010; 5: 733-740
• 14 Christensen I, Lu B, Yang N, Huang K, Wang P, Tian N. The susceptibility of retinal ganglion cells to glutamatergic excitotoxicity is type-specific. Front Neurosci 2019; 13: 219 DOI: 10.3389/fnins.2019.00219.
• 15 Gobbo-Neto L, Lopes NP. Online identification of chlorogenic acids, sesquiterpene lactones, and flavonoids in the Brazilian arnica Lychnophora ericoides Mart. (Asteraceae) leaves by HPLC-DAD-MS and HPLC-DAD-MS/MS and a validated HPLC-DAD method for their simultaneous analysis. J Agric Food Chem 2008; 56: 1193-1204 DOI: 10.1021/jf072812l.
• 16 Mortari MR, Cunha AO, Ferreira LB, dos Santos WF. Neurotoxins from invertebrates as anticonvulsants: From basic research to therapeutic application. Pharmacol Ther 2007; 114: 171-183 DOI: 10.1016/j.pharmthera.2007.01.009.
• 17 Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87: 450-454 DOI: 10.1111/j.1755-3768.2008.01459.x.
• 18 Guizzo R, Rodrigues MCA, Coutinho-Netto J, Silva ARM, Coimbra NC, Santos WF. Neuroprotection in acute ischemia and ischemia/reperfusion in rat retina. Int J Pharmacol 2005; 1: 369-375 DOI: 10.3923/ijp.2005.369.375.
• 19 Louzada-Júnior P, Dias JJ, Santos WF, Lachat JJ, Bradford HF, Coutinho-Netto J. Glutamate release in experimental ischaemia of the retina: an approach using microdialysis. J Neurochem 1992; 59: 358-363
• 20 Belov Kirdajova D, Kriska J, Tureckova J, Anderova M. Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells. Front Cell Neurosci 2020; 14: 51 DOI: 10.3389/fncel.2020.00051.
• 21 Fisher M. New approaches to neuroprotective drug development. Stroke 2011; 42: S24-S27 DOI: 10.1161/STROKEAHA.110.592394.
• 22 Mondolot L, La Fisca P, Buatois B, Talansier E, de Kochko A, Campa C. Evolution in caffeoylquinic acid content and histolocalization during Coffea canephora leaf development. Ann Bot 2006; 98: 33-40 DOI: 10.1093/aob/mcl080.
• 23 Abdel Motaal A, Ezzat SM, Tadros MG, El-Askary HI. In vivo anti-inflammatory activity of caffeoylquinic acid derivatives from Solidago virgaurea in rats. Pharm Biol 2016; 54: 2864-2870 DOI: 10.1080/13880209.2016.1190381.
• 24 Nakajima Y, Shimazawa M, Mishima S, Hara H. Water extract of propolis and its main constituents, caffeoylquinic acid derivatives, exert neuroprotective effects via antioxidant actions. Life Sci 2007; 80: 370-377 DOI: 10.1016/j.lfs.2006.09.017.
• 25 Wu MY, Yiang GT, Liao WT, Tsai AP, Cheng YL, Cheng PW, Li CY, Li CJ. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem 2018; 46: 1650-1667 DOI: 10.1159/000489241.
• 26 Nabavi SF, Tejada S, Setzer WN, Gortzi O, Sureda A, Braidy N, Daglia M, Manayi A, Nabavi SM. Chlorogenic acid and mental diseases: From chemistry to medicine. Curr Neuropharmacol 2017; 15: 471-479 DOI: 10.2174/1570159X14666160325120625.
• 27 Dajas F, Andrés AC, Florencia A, Carolina E, Felicia RM. Neuroprotective actions of flavones and flavonols: Mechanisms and relationship to flavonoid structural features. Cent Nerv Syst Agents Med Chem 2013; 13: 30-35 DOI: 10.2174/1871524911313010005.
• 28 Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative stress and inflammation: What polyphenols can do for us?. Oxid Med Cell Longev 2016; 2016: 7432797 DOI: 10.1155/2016/7432797.
• 29 Li X, Li K, Xie H, Xie Y, Li Y, Zhao X, Jiang X, Chen D. Antioxidant and cytoprotective effects of the Di-O-Caffeoylquinic acid family: The mechanism, structure-activity relationship, and conformational effect. Molecules 2018; 23: 222 DOI: 10.3390/molecules23010222.
• 30 Kumar G, Paliwal P, Mukherjee S, Patnaik N, Krishnamurthy S, Patnaik R. Pharmacokinetics and brain penetration study of chlorogenic acid in rats. Xenobiotica 2019; 49: 339-345 DOI: 10.1080/00498254.2018.1445882.
• 31 Gurel A, Armutcu F, Hosnuter M, Unalacak M, Kargi E, Altinyazar C. Caffeic acid phenethyl ester improves oxidative organ damage in rat model of thermal trauma. Physiol Res 2004; 53: 675-682
• 32 Ozguner F, Bardak Y, Comlekci S. Protective effects of melatonin and caffeic acid phenethyl ester against retinal oxidative stress in long-term use of mobile phone: a comparative study. Mol Cell Biochem 2006; 282: 83-88 DOI: 10.1007/s11010-006-1267-0.
• 33 Shi Y, Wu X, Gong Y, Qiu Y, Zhang H, Huang Z, Su K. Protective effects of caffeic acid phenethyl ester on retinal ischemia/reperfusion injury in rats. Curr Eye Res 2010; 35: 930-937 DOI: 10.3109/02713683.2010.494820.
• 34 Jang H, Choi Y, Ahn HR, Jung SH, Lee CY. Effects of phenolic acid metabolites formed after chlorogenic acid consumption on retinal degeneration in vivo . Mol Nutr Food Res 2015; 59: 1918-1929 DOI: 10.1002/mnfr.201400897.
• 35 Shin JY, Sohn J, Park KH. Chlorogenic acid decreases retinal vascular hyperpermeability in diabetic rat model. J Korean Med Sci 2013; 28: 608-613 DOI: 10.3346/jkms.2013.28.4.608.
• 36 Feng R, Lu Y, Bowman LL, Qian Y, Castranova V, Ding M. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem 2005; 280: 27888-27895 DOI: 10.1074/jbc.M503347200.
• 37 Nwafor EO, Lu P, Zhang Y, Liu R, Peng H, Xing B, Liu Y, Li Z, Zhang K, Zhang Y, Liu Z. Chlorogenic acid: Potential source of natural drugs for the therapeutics of fibrosis and cancer. Transl Oncol 2022; 15: 101294 DOI: 10.1016/j.tranon.2021.101294.
• 38 Chen D, Pan D, Tang S, Tan Z, Zhang Y, Fu Y, Lü G, Huang Q. Administration of chlorogenic acid alleviates spinal cord injury via TLR4/NF-κB and p38 signaling pathway anti-inflammatory activity. Mol Med Rep 2018; 17: 1340-1346 DOI: 10.3892/mmr.2017.7987.
• 39 Gauthier AC, Liu J. Epigenetics and signaling pathways in glaucoma. Biomed Res Int 2017; 2017: 5712341 DOI: 10.1155/2017/5712341.
• 40 Vukelić I, Detel D, Pučar LB, Potočnjak I, Buljević S, Domitrović R. Chlorogenic acid ameliorates experimental colitis in mice by suppressing signaling pathways involved in inflammatory response and apoptosis. Food Chem Toxicol 2018; 121: 140-150 DOI: 10.1016/j.fct.2018.08.061.
• 41 Mikami Y, Yamazawa T. Chlorogenic acid, a polyphenol in coffee, protects neurons against glutamate neurotoxicity. Life Sci 2015; 139: 69-74 DOI: 10.1016/j.lfs.2015.08.005.
• 42 Hung YC, Kuo YH, Hsieh PW, Hsieh TY, Kuo JR, Wang SJ. Chlorogenic acid decreases glutamate release from rat cortical nerve terminals by P/Q-Type Ca²⁺ channel suppression: A possible neuroprotective mechanism. Int J Mol Sci 2021; 22: 11447 DOI: 10.3390/ijms222111447.
• 43 Socodato R, Portugal CC, Canedo T, Domith I, Oliveira NA, Paes-de-Carvalho R, Relvas JB, Cossenza M. c-Src deactivation by the polyphenol 3-O-caffeoylquinic acid abrogates reactive oxygen species-mediated glutamate release from microglia and neuronal excitotoxicity. Free Radic Biol Med 2015; 79: 45-55 DOI: 10.1016/j.freeradbiomed.2014.11.019.
• 44 Moreira EA, Pilon AC, Andrade LE, Lopes NP. New perspectives on chlorogenic acid accumulation in harvested leaf tissue: Impact on traditional medicine preparations. ACS Omega 2018; 3: 18380-18386 DOI: 10.1021/acsomega.8b02409.
• 45 Schmued LC, Stowers CC, Scallet AC, Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 2005; 1035: 24-31 DOI: 10.1016/j.brainres.2004.11.054.